The purpose of this study is to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB.
This study will also evaluate the safety and tolerability of mirabegron in pediatric participants with OAB and evaluate the pharmacokinetics after multiple dose administration of mirabegron in pediatric participants with OAB.
The study consists of 3 periods (Screening period/urotherapy (4 weeks); Double-blind, placebo-controlled period (12 weeks); Follow-up period (2 weeks)) for a total duration of 18 weeks.
| Condition | Overactive Bladder (OAB), Pharmacokinetics of Mirabegron |
|---|---|
| Treatment | Placebo, mirabegron |
| Clinical Study Identifier | NCT04641975 |
| Sponsor | Astellas Pharma Global Development, Inc. |
| Last Modified on | 15 September 2023 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.